In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species

Anna Marchese, Angelo Salerno, Adelaide Pesce, Eugenio A. Debbia, Gian Carlo Schito

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Background: Rifaximin is a rifamycin derivative characterized by a wide antibacterial activity. This drug is neither absorbed by the gastrointestinal tract nor inactivated by gastric juices, and exerts its action entirely within the intestinal lumen. Methods: In this study, the activity of this antibiotic was compared with that of metronidazole and vancomycin against 93 Clostridium difficile isolates. The rate of emergence of bacteria spontaneously resistant to the new compound was also evaluated in relation to representative gram-positive and gram-negative strains. In terms of MIC50 values, rifaxirain showed an intrinsic activity superior to that of the other agents. The emergence of spontaneously resistant strains was assessed with 46 aerobic (staphylococci, enterococci, Proteus spp., Citrobacter freundii, Providencia rettgeri, enteropathogenic, enteroinvasive, enterotoxigenic and enterohemorrhagic Escherichia coli, and Salmonella enteritidis) and anaerobic (Clostridium spp., Bacteroides spp., Fusobacterium nucleatum and Peptococcus spp.) pathogens, most of them also ammonium producers. Two different methods, broth and agar dilution, were employed. Results: When liquid medium was employed, bacteria capable of sustained growth in 100 μg/ml of rifaximin were obtained after 2-5 transfers with grampositive aerobic cocci, 2-3 transfers with gram-negative aerobic strains and 2-5 transfers with anaerobic species. At the highest dose used with the agar dilution method (8 x MIC), the frequency of emergence of spontaneously resistant mutants ranged from <1 x 10-9 to 1.6 x 10-8 with gram-positive aerobic and anaerobic cocci, while with aerobic and anaerobic gram-negative bacteria, this value ranged from <1 x 10-9 to 1.7 x 10-7. C. difficile showed a particularly low incidence of spontaneously resistant mutants (<1 x 10-9). The low incidence of resistant subpopulations selected by levels of 8 x MIC of rifaximin suggests that the high levels of the drug which were reached in the gastrointestinal lumen may further prevent the selection of mutants. Conclusion: The low toxicity, broad antibacterial activity and very poor absorption from the gastrointestinal tract of rifaximin suggest a potential therapeutic use for this drug in gastrointestinal diseases, as well as in the management of patients with cirrhosis and chronic portal-systemic encephalopathy. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish
Pages (from-to)253-266
Number of pages14
JournalChemotherapy
Volume46
Issue number4
Publication statusPublished - 2000

Fingerprint

rifaximin
Aerobic Bacteria
Anaerobic Bacteria
Clostridium difficile
Metronidazole
Vancomycin
Ammonia
Agar
Gastrointestinal Tract
Peptococcus
Gram-Negative Aerobic Bacteria
Gram-Negative Anaerobic Bacteria
Chronic Brain Damage
Providencia
Pharmaceutical Preparations
Fusobacterium nucleatum
Citrobacter freundii
Enterohemorrhagic Escherichia coli
Bacteria
Enterotoxigenic Escherichia coli

Keywords

  • Clostridium difficile
  • Rifaximin
  • Spontaneous resistance

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. / Marchese, Anna; Salerno, Angelo; Pesce, Adelaide; Debbia, Eugenio A.; Schito, Gian Carlo.

In: Chemotherapy, Vol. 46, No. 4, 2000, p. 253-266.

Research output: Contribution to journalArticle

@article{24c5c6153aa14ccfa04c1ec0c4a486a2,
title = "In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species",
abstract = "Background: Rifaximin is a rifamycin derivative characterized by a wide antibacterial activity. This drug is neither absorbed by the gastrointestinal tract nor inactivated by gastric juices, and exerts its action entirely within the intestinal lumen. Methods: In this study, the activity of this antibiotic was compared with that of metronidazole and vancomycin against 93 Clostridium difficile isolates. The rate of emergence of bacteria spontaneously resistant to the new compound was also evaluated in relation to representative gram-positive and gram-negative strains. In terms of MIC50 values, rifaxirain showed an intrinsic activity superior to that of the other agents. The emergence of spontaneously resistant strains was assessed with 46 aerobic (staphylococci, enterococci, Proteus spp., Citrobacter freundii, Providencia rettgeri, enteropathogenic, enteroinvasive, enterotoxigenic and enterohemorrhagic Escherichia coli, and Salmonella enteritidis) and anaerobic (Clostridium spp., Bacteroides spp., Fusobacterium nucleatum and Peptococcus spp.) pathogens, most of them also ammonium producers. Two different methods, broth and agar dilution, were employed. Results: When liquid medium was employed, bacteria capable of sustained growth in 100 μg/ml of rifaximin were obtained after 2-5 transfers with grampositive aerobic cocci, 2-3 transfers with gram-negative aerobic strains and 2-5 transfers with anaerobic species. At the highest dose used with the agar dilution method (8 x MIC), the frequency of emergence of spontaneously resistant mutants ranged from <1 x 10-9 to 1.6 x 10-8 with gram-positive aerobic and anaerobic cocci, while with aerobic and anaerobic gram-negative bacteria, this value ranged from <1 x 10-9 to 1.7 x 10-7. C. difficile showed a particularly low incidence of spontaneously resistant mutants (<1 x 10-9). The low incidence of resistant subpopulations selected by levels of 8 x MIC of rifaximin suggests that the high levels of the drug which were reached in the gastrointestinal lumen may further prevent the selection of mutants. Conclusion: The low toxicity, broad antibacterial activity and very poor absorption from the gastrointestinal tract of rifaximin suggest a potential therapeutic use for this drug in gastrointestinal diseases, as well as in the management of patients with cirrhosis and chronic portal-systemic encephalopathy. Copyright (C) 2000 S. Karger AG, Basel.",
keywords = "Clostridium difficile, Rifaximin, Spontaneous resistance",
author = "Anna Marchese and Angelo Salerno and Adelaide Pesce and Debbia, {Eugenio A.} and Schito, {Gian Carlo}",
year = "2000",
language = "English",
volume = "46",
pages = "253--266",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species

AU - Marchese, Anna

AU - Salerno, Angelo

AU - Pesce, Adelaide

AU - Debbia, Eugenio A.

AU - Schito, Gian Carlo

PY - 2000

Y1 - 2000

N2 - Background: Rifaximin is a rifamycin derivative characterized by a wide antibacterial activity. This drug is neither absorbed by the gastrointestinal tract nor inactivated by gastric juices, and exerts its action entirely within the intestinal lumen. Methods: In this study, the activity of this antibiotic was compared with that of metronidazole and vancomycin against 93 Clostridium difficile isolates. The rate of emergence of bacteria spontaneously resistant to the new compound was also evaluated in relation to representative gram-positive and gram-negative strains. In terms of MIC50 values, rifaxirain showed an intrinsic activity superior to that of the other agents. The emergence of spontaneously resistant strains was assessed with 46 aerobic (staphylococci, enterococci, Proteus spp., Citrobacter freundii, Providencia rettgeri, enteropathogenic, enteroinvasive, enterotoxigenic and enterohemorrhagic Escherichia coli, and Salmonella enteritidis) and anaerobic (Clostridium spp., Bacteroides spp., Fusobacterium nucleatum and Peptococcus spp.) pathogens, most of them also ammonium producers. Two different methods, broth and agar dilution, were employed. Results: When liquid medium was employed, bacteria capable of sustained growth in 100 μg/ml of rifaximin were obtained after 2-5 transfers with grampositive aerobic cocci, 2-3 transfers with gram-negative aerobic strains and 2-5 transfers with anaerobic species. At the highest dose used with the agar dilution method (8 x MIC), the frequency of emergence of spontaneously resistant mutants ranged from <1 x 10-9 to 1.6 x 10-8 with gram-positive aerobic and anaerobic cocci, while with aerobic and anaerobic gram-negative bacteria, this value ranged from <1 x 10-9 to 1.7 x 10-7. C. difficile showed a particularly low incidence of spontaneously resistant mutants (<1 x 10-9). The low incidence of resistant subpopulations selected by levels of 8 x MIC of rifaximin suggests that the high levels of the drug which were reached in the gastrointestinal lumen may further prevent the selection of mutants. Conclusion: The low toxicity, broad antibacterial activity and very poor absorption from the gastrointestinal tract of rifaximin suggest a potential therapeutic use for this drug in gastrointestinal diseases, as well as in the management of patients with cirrhosis and chronic portal-systemic encephalopathy. Copyright (C) 2000 S. Karger AG, Basel.

AB - Background: Rifaximin is a rifamycin derivative characterized by a wide antibacterial activity. This drug is neither absorbed by the gastrointestinal tract nor inactivated by gastric juices, and exerts its action entirely within the intestinal lumen. Methods: In this study, the activity of this antibiotic was compared with that of metronidazole and vancomycin against 93 Clostridium difficile isolates. The rate of emergence of bacteria spontaneously resistant to the new compound was also evaluated in relation to representative gram-positive and gram-negative strains. In terms of MIC50 values, rifaxirain showed an intrinsic activity superior to that of the other agents. The emergence of spontaneously resistant strains was assessed with 46 aerobic (staphylococci, enterococci, Proteus spp., Citrobacter freundii, Providencia rettgeri, enteropathogenic, enteroinvasive, enterotoxigenic and enterohemorrhagic Escherichia coli, and Salmonella enteritidis) and anaerobic (Clostridium spp., Bacteroides spp., Fusobacterium nucleatum and Peptococcus spp.) pathogens, most of them also ammonium producers. Two different methods, broth and agar dilution, were employed. Results: When liquid medium was employed, bacteria capable of sustained growth in 100 μg/ml of rifaximin were obtained after 2-5 transfers with grampositive aerobic cocci, 2-3 transfers with gram-negative aerobic strains and 2-5 transfers with anaerobic species. At the highest dose used with the agar dilution method (8 x MIC), the frequency of emergence of spontaneously resistant mutants ranged from <1 x 10-9 to 1.6 x 10-8 with gram-positive aerobic and anaerobic cocci, while with aerobic and anaerobic gram-negative bacteria, this value ranged from <1 x 10-9 to 1.7 x 10-7. C. difficile showed a particularly low incidence of spontaneously resistant mutants (<1 x 10-9). The low incidence of resistant subpopulations selected by levels of 8 x MIC of rifaximin suggests that the high levels of the drug which were reached in the gastrointestinal lumen may further prevent the selection of mutants. Conclusion: The low toxicity, broad antibacterial activity and very poor absorption from the gastrointestinal tract of rifaximin suggest a potential therapeutic use for this drug in gastrointestinal diseases, as well as in the management of patients with cirrhosis and chronic portal-systemic encephalopathy. Copyright (C) 2000 S. Karger AG, Basel.

KW - Clostridium difficile

KW - Rifaximin

KW - Spontaneous resistance

UR - http://www.scopus.com/inward/record.url?scp=0033932776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033932776&partnerID=8YFLogxK

M3 - Article

VL - 46

SP - 253

EP - 266

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 4

ER -